Literature DB >> 23730405

Genetic grouping of medulloblastomas by representative markers in pathologic diagnosis.

Hye Sook Min1, Ji Yeoun Lee, Seung-Ki Kim, Sung-Hye Park.   

Abstract

A recent analysis of the genetic features of medulloblastoma (MB) suggested classification into distinct subgroups according to gene expression profiles, including the Wingless signaling pathway-activated group (WNT group), the Sonic Hedgehog signaling pathway-activated group (SHH group), group 3, and group 4. To classify MB according to genetic features in practice, we analyzed 74 MBs using representative markers of each group. Based on immunohistochemistries (IHC), cytogenetic alterations, and a CTNNB1 mutation study, the patients were divided into the following three groups: cases showing nuclear β-catenin and/or CTNNB1 mutation and/or monosomy 6 were included in the WNT group (14/74, 18.9%); cases expressing GAB1 were included in the SHH group (15/74, 20.2%); cases that did not show positivity for markers of the WNT or SHH group were included in the non-WNT/SHH group (45/74, 60.6%). Immunoexpression of NPR3 seemed to lack sensitivity for classifying group 3, showing diffuse positivity in only two cases. KCNA1 was not specific to group 4 because it was expressed in all groups. Cases in the WNT group showed a slightly better survival than those in the SHH or non-WNT/SHH group, although additional cases are required for statistical significance. Isochromosome 17q (P = .002) and the large cell/anaplastic variant (P = .002) were demonstrated to be poor prognostic indicators in multivariate analysis. The representative IHC and cytogenetic data facilitated the division of MBs into the WNT and SHH groups; however, more specific markers should be added for the identification of group 3 and group 4 in practice.

Entities:  

Year:  2013        PMID: 23730405      PMCID: PMC3660794          DOI: 10.1593/tlo.12382

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  26 in total

1.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

Authors:  Yoon-Jae Cho; Aviad Tsherniak; Pablo Tamayo; Sandro Santagata; Azra Ligon; Heidi Greulich; Rameen Berhoukim; Vladimir Amani; Liliana Goumnerova; Charles G Eberhart; Ching C Lau; James M Olson; Richard J Gilbertson; Amar Gajjar; Olivier Delattre; Marcel Kool; Keith Ligon; Matthew Meyerson; Jill P Mesirov; Scott L Pomeroy
Journal:  J Clin Oncol       Date:  2010-11-22       Impact factor: 44.544

2.  Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization.

Authors:  D A Reardon; E Michalkiewicz; J M Boyett; J E Sublett; R E Entrekin; S T Ragsdale; M B Valentine; F G Behm; H Li; R L Heideman; L E Kun; D N Shapiro; A T Look
Journal:  Cancer Res       Date:  1997-09-15       Impact factor: 12.701

3.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.

Authors:  David W Ellison; James Dalton; Mehmet Kocak; Sarah Leigh Nicholson; Charles Fraga; Geoff Neale; Anna M Kenney; Dan J Brat; Arie Perry; William H Yong; Roger E Taylor; Simon Bailey; Steven C Clifford; Richard J Gilbertson
Journal:  Acta Neuropathol       Date:  2011-01-26       Impact factor: 17.088

4.  Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct.

Authors:  Paul A Northcott; Thomas Hielscher; Adrian Dubuc; Stephen Mack; David Shih; Marc Remke; Hani Al-Halabi; Steffen Albrecht; Nada Jabado; Charles G Eberhart; Wieslawa Grajkowska; William A Weiss; Steven C Clifford; Eric Bouffet; James T Rutka; Andrey Korshunov; Stefan Pfister; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2011-06-17       Impact factor: 17.088

5.  Accumulation of genomic aberrations during clinical progression of medulloblastoma.

Authors:  Andrey Korshunov; Axel Benner; Marc Remke; Peter Lichter; Andreas von Deimling; Stefan Pfister
Journal:  Acta Neuropathol       Date:  2008-08-15       Impact factor: 17.088

6.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays.

Authors:  D Pinkel; R Segraves; D Sudar; S Clark; I Poole; D Kowbel; C Collins; W L Kuo; C Chen; Y Zhai; S H Dairkee; B M Ljung; J W Gray; D G Albertson
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

7.  Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement.

Authors:  Gabriel A Bien-Willner; Dolores López-Terrada; Meena B Bhattacharjee; Kayuri U Patel; Pawel Stankiewicz; James R Lupski; John D Pfeifer; Arie Perry
Journal:  Neuro Oncol       Date:  2012-05-09       Impact factor: 12.300

8.  Molecular subgroups of medulloblastoma: the current consensus.

Authors:  Michael D Taylor; Paul A Northcott; Andrey Korshunov; Marc Remke; Yoon-Jae Cho; Steven C Clifford; Charles G Eberhart; D Williams Parsons; Stefan Rutkowski; Amar Gajjar; David W Ellison; Peter Lichter; Richard J Gilbertson; Scott L Pomeroy; Marcel Kool; Stefan M Pfister
Journal:  Acta Neuropathol       Date:  2011-12-02       Impact factor: 17.088

9.  Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples.

Authors:  Paul A Northcott; David J H Shih; Marc Remke; Yoon-Jae Cho; Marcel Kool; Cynthia Hawkins; Charles G Eberhart; Adrian Dubuc; Toumy Guettouche; Yoslayma Cardentey; Eric Bouffet; Scott L Pomeroy; Marco Marra; David Malkin; James T Rutka; Andrey Korshunov; Stefan Pfister; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2011-11-06       Impact factor: 17.088

10.  Clinical and molecular stratification of disease risk in medulloblastoma.

Authors:  R Gilbertson; C Wickramasinghe; R Hernan; V Balaji; D Hunt; D Jones-Wallace; J Crolla; R Perry; J Lunec; A Pearson; D Ellison
Journal:  Br J Cancer       Date:  2001-09-01       Impact factor: 7.640

View more
  10 in total

1.  Clinicopathological analysis of UHRF1 expression in medulloblastoma tissues and its regulation on tumor cell proliferation.

Authors:  Zhen-Yu Zhang; Jia-Jun Cai; Jin Hong; Kay Ka-Wai Li; Zhou Ping; Yin Wang; Ho-Keung Ng; Yu Yao; Ying Mao
Journal:  Med Oncol       Date:  2016-07-23       Impact factor: 3.064

Review 2.  Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation.

Authors:  Eduardo Cambruzzi
Journal:  Childs Nerv Syst       Date:  2018-03-26       Impact factor: 1.475

Review 3.  Medulloblastomics revisited: biological and clinical insights from thousands of patients.

Authors:  Volker Hovestadt; Olivier Ayrault; Fredrik J Swartling; Giles W Robinson; Stefan M Pfister; Paul A Northcott
Journal:  Nat Rev Cancer       Date:  2019-12-09       Impact factor: 69.800

4.  SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis.

Authors:  Yong-Xiao Li; Zhen-Wei Yu; Tao Jiang; Li-Wei Shao; Yan Liu; Na Li; Yu-Feng Wu; Chen Zheng; Xiao-Yu Wu; Ming Zhang; Dan-Feng Zheng; Xue-Ling Qi; Min Ding; Jing Zhang; Qing Chang
Journal:  Cancer Sci       Date:  2018-02-20       Impact factor: 6.716

Review 5.  Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas.

Authors:  Otília Menyhárt; Felice Giangaspero; Balázs Győrffy
Journal:  J Hematol Oncol       Date:  2019-03-15       Impact factor: 17.388

6.  Immunohistochemical staining of LEF-1 is a useful marker for distinguishing WNT-activated medulloblastomas.

Authors:  Depeng Wang; Jie Gong; Hui Zhang; Yulu Liu; Nannan Sun; Xiaomeng Hao; Kun Mu
Journal:  Diagn Pathol       Date:  2022-09-13       Impact factor: 3.196

Review 7.  Molecular variants and mutations in medulloblastoma.

Authors:  Kristin Schroeder; Sri Gururangan
Journal:  Pharmgenomics Pers Med       Date:  2014-02-04

8.  Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors.

Authors:  Gabriel A Bien-Willner; Robi D Mitra
Journal:  Acta Neuropathol Commun       Date:  2014-07-17       Impact factor: 7.801

9.  MiR-1253 exerts tumor-suppressive effects in medulloblastoma via inhibition of CDK6 and CD276 (B7-H3).

Authors:  Ranjana K Kanchan; Naveenkumar Perumal; Pranita Atri; Ramakanth Chirravuri Venkata; Ishwor Thapa; David L Klinkebiel; Andrew M Donson; Deborah Perry; Michael Punsoni; Geoffrey A Talmon; Donald W Coulter; Daniel R Boue'; Matija Snuderl; Mohd W Nasser; Surinder K Batra; Rajeev Vibhakar; Sidharth Mahapatra
Journal:  Brain Pathol       Date:  2020-03-30       Impact factor: 6.508

Review 10.  Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment.

Authors:  Sutapa Ray; Nagendra K Chaturvedi; Kishor K Bhakat; Angie Rizzino; Sidharth Mahapatra
Journal:  Diagnostics (Basel)       Date:  2021-12-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.